Primary fallopian tube carcinoma: Preoperative diagnostic dilemma

Autor: Shalini Bhalla, Shalini Rawat, Sameer Gupta

Publikováno v: Indian Journal of Health Sciences and Biomedical Research KLEU, Vol 16, Iss 2, Pp 324-326 (2023)

Primary fallopian tube carcinoma is an uncommon female genital tract malignancy that resembles epithelial ovarian neoplasm clinically and radiologically. We present a case of 49-year-old woman with postmenopausal intermittent vaginal bleeding, lower

Externí odkaz: https://doaj.org/article/75ffa85a26ec4101acc6865be7c7825c

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Multicentric adrenocorticotropic hormone -producing steroid cell tumor of the fallopian tube & broad ligament in a 15 year old girl

Autor: Mohammed El-Sayed, Ahmed Setit, Gehad A. Saleh, Omar Hamdy, Islam H. Metwally, Reham Naguib, Sara A. Eldegwi

Publikováno v: Gynecological Endocrinology. 36:835-838

Steroid cell tumors occur usually in the ovaries with very few reported cases of extra-ovarian origin. Our patient was a fifteen year old female, complaining from secondary amenorrhea and voice deepening. Values of serum cortisol, DHEA, FSHLH were no

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4b43cefd9770ca9a9b9fb59cf7f5db7
https://doi.org/10.1080/09513590.2020.1731451

The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder allele BRCA2 6174delT

Autor: Finch, Amy, Metcalfe, Kelly, Akbari, Mohammad, Friedman, Eitan, Tung, Nadine, Rosen, Barry, Eisen, Andrea, Karlan, Beth, Foulkes, William, Neuhausen, Susan L, Senter, Leigha, McKinnon, Wendy, Elser, Christine, Sun, Ping, Narod, Steven A, Fruscio Robert

Publikováno v: Clinical geneticsREFERENCES. 101(3)

Approximately 1% of the Ashkenazi Jewish population carries the BRCA2 6174delT (c.5946del) pathogenic variant. It is important to have accurate knowledge of the risks of breast and ovarian cancer associated with this specific variant so that women ma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c7e7726940e6831df1f1df84be3ec89
https://pubmed.ncbi.nlm.nih.gov/34897671

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Autor: Alla Lisyanskaya, Giovanni Scambia, Amit M. Oza, Ralph Bloomfield, Cara Mathews, Paul DiSilvestro, Alexandra Leary, Michael Friedlander, Ana Oaknin, Anne Floquet, Nicoletta Colombo, Carol Aghajanian, Susana Banerjee, Kathleen N. Moore, William H. Bradley, Elizabeth S. Lowe, Byoung Gie Kim, Antonio González-Martín, Gabe S. Sonke, Charlie Gourley, Joyce F. Liu

Publikováno v: Moore, K, Colombo, N, Scambia, G, Kim, B-G, Oaknin, A, Friedlander, M, Lisyanskaya, A, Floquet, A, Leary, A, Sonke, G S, Gourley, C, Banerjee, S, Oza, A, Gonzalez-Martin, A, Aghajanian, C, Bradley, W, Mathews, C, Liu, J, Lowe, E S, Bloomfield, R & DiSilvestro, P 2018, ' Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer ', New England Journal of Medicine, vol. 379, no. 26, pp. 2495-2505 . https://doi.org/10.1056/NEJMoa1810858

BACKGROUND: Most women with newly diagnosed advanced ovarian cancer have a relapse within 3 years after standard treatment with surgery and platinum-based chemotherapy. The benefit of the oral poly(adenosine diphosphate–ribose) polymerase inhibitor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ad80e9aab4426e67812b2d230957e59
https://doi.org/10.1056/nejmoa1810858